Implementation of mechanism of action biology-driven early drug development for children with cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065560" target="_blank" >RIV/00159816:_____/16:00065560 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00092086 RIV/65269705:_____/16:00065560 RIV/00209805:_____/16:N0000087

Result on the web

<a href="http://dx.doi.org/10.1016/j.ejca.2016.04.001" target="_blank" >http://dx.doi.org/10.1016/j.ejca.2016.04.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejca.2016.04.001" target="_blank" >10.1016/j.ejca.2016.04.001</a>

Result language

angličtina

Original language name

Implementation of mechanism of action biology-driven early drug development for children with cancer

Original language description

An urgent need remains for new paediatric oncology drugs to cure children who die from cancer and to reduce drug-related sequelae in survivors. In 2007, the European Paediatric Regulation came into law requiring industry to create paediatric drug (all types of medicinal products) development programmes alongside those for adults. Unfortunately, paediatric drug development is still largely centred on adult conditions and not a mechanism of action (MoA)-based model, even though this would be more logical for childhood tumours as these have much fewer non-synonymous coding mutations than adult malignancies. Recent large-scale sequencing by International Genome Consortium and Paediatric Cancer Genome Project has further shown that the genetic and epigenetic repertoire of driver mutations in specific childhood malignancies differs from more common adult-type malignancies. To bring about much needed change, a Paediatric Platform, ACCELERATE, was proposed in 2013 by the Cancer Drug Development Forum, Innovative Therapies for Children with Cancer, the European Network for Cancer Research in Children and Adolescents and the European Society for Paediatric Oncology. The Platform, comprising multiple stakeholders in paediatric oncology, has three working groups, one with responsibility for promoting and developing high-quality MoA-informed paediatric drug development programmes, including specific measures for adolescents. Key is the establishment of a freely accessible aggregated database of paediatric biological tumour drug targets to be aligned with an aggregated pipeline of drugs. This will enable prioritisation and conduct of early phase clinical paediatric trials to evaluate these drugs against promising therapeutic targets and to generate clinical paediatric efficacy and safety data in an accelerated time frame.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Cancer

ISSN

0959-8049

e-ISSN

—

Volume of the periodical

62

Issue of the periodical within the volume

Jul

Country of publishing house

GB - UNITED KINGDOM

Number of pages

8

Pages from-to

124-131

UT code for WoS article

000377385100014

EID of the result in the Scopus database

—